NCT05857332View on ClinicalTrials.gov

SG1906 for CLDN18.2-Positive Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

August 30, 2027

Conditions
Locally Advanced Unresectable or Metastatic Solid Tumors
Interventions
DRUG

SG1906

Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.

Trial Locations (9)

100039

RECRUITING

Chinese PLA General Hospital, Beijing

110002

RECRUITING

The First Hospital of China Medical University, Shenyang

110801

RECRUITING

Liaoning Cancer Hospital, Shenyang

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310009

RECRUITING

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

510655

RECRUITING

The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

Unknown

RECRUITING

The First Affiliated Hospital Of Xiamen University, Xiamen

030013

RECRUITING

Shanxi Cancer Hospital, Taiyuan

All Listed Sponsors
lead

Hangzhou Sumgen Biotech Co., Ltd.

INDUSTRY